Overview

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and markets injectable and inhalation products. The company focuses on products with complex regulatory requirements, ranging from drug-device combinations to biosimilars.

Therapeutic areas

API / Drug Master Files

Amphastar Pharmaceuticals, Inc. holds 16 active (18 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • PHYTONADIONE USPActive2023-09-30
  • BUDESONIDE USPActive2019-08-22
  • FORMOTEROL FUMARATE USPActive2019-08-09
  • TERIPARATIDE USPActive2019-05-19
  • EPINEPHRINE USPActive2018-08-08
  • INSULIN ASPART USPActive2018-05-16
  • MEDROXYPROGESTERONE ACETATE, USPActive2018-02-08
  • IPRATROPIUM BROMIDE USPActive2017-11-28
  • PROTAMINE SULFATE USPActive2016-09-16
  • ISOPROTERENOL HYDROCHLORIDE USPActive2015-11-09
  • SODIUM NITROPRUSSIDE USPActive2015-11-03
  • SALMETEROL XINAFOATE, USPActive2015-08-11
  • FLUTICASONE PROPIONATE, USPActive2015-06-29
  • BECLOMETHASONE DIPROPIONATEActive2014-03-06
  • SEMI-PURIFIED HEPARIN SODIUMActive2012-05-25

Showing 15 of 18 Drug Master Files.

FDA compliance signals

10 FDA enforcement records linked to this company.

  • recall — Class II2017-09-06

    Crystallization: Particulate matter (Ketorolac Calcium Salt) was observed from several lots of retained samples.

  • 4832013-02-06

    Scientifically sound laboratory controls

  • 4832013-02-06

    Actual yield, % of theoretical yield

  • 4832013-02-06

    Establish reliability of supplier's C of A

  • 4832012-06-28

    Late submission of 15-day report

  • 4832012-06-28

    Training--operations, GMPs, written procedures

  • 4832012-06-28

    Investigations of discrepancies, failures

  • 4832012-06-28

    Failure to meet specifications

  • 4832012-06-28

    Failure to submit ADE report

  • 4832012-06-28

    Mfg and control changes not requiring a supplemental app.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.